Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baricitinib (Primary)
Indications Alopecia areata
Focus Registrational; Therapeutic Use
Acronyms BRAVE-AA2
Sponsors Eli Lilly and Company

Most Recent Events

31 Jan 2025 Status changed from active, no longer recruiting to completed.
09 Sep 2024 Planned End Date changed from 29 Jul 2024 to 1 Dec 2024.
01 Mar 2024 Results (from studies BRAVE-AA1 and BRAVE-AA2) assessing efficacy and safety of baricitinib for severe AA through 104 weeks of continuous therapy published in the Journal of the European Academy of Dermatology and Venereology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com